RÉSUMÉ
Treatment of SIV-infected rhesus macaques with short-term antiretroviral therapy (ART) and partially overlapping infusions of antibody to integrin α4ß7 was reported to induce durable posttreatment viral suppression. In an attempt to replicate those observations, we treated macaques infected with the same virus and with the same ART and monoclonal antibody (mAb) regimens (anti-α4ß7 versus control mAb). Sequencing demonstrated that the virus used was actually SIVmac239-nef-stop, not wild-type SIVmac239. A positive correlation was found at 2 weeks after infection between the frequency of repair of attenuated Nef-STOP virus to pathogenic Nef-OPEN and plasma SIV RNA levels. Levels of plasma viremia before the first antibody infusion and preinfection levels of α4ß7 hi CD4+ T cells, but not treatment with antibody to α4ß7 , correlated with levels of viral replication upon discontinuation of all treatments. Follow-up plasma viremia, peripheral blood CD4+ T cell counts, and lymph node and rectal tissue viral load were not significantly different between anti-α4ß7 and control mAb groups.
Sujet(s)
Anticorps monoclonaux/usage thérapeutique , Infections à VIH/thérapie , Intégrine alpha4/immunologie , Chaines bêta des intégrines/immunologie , Syndrome d'immunodéficience acquise du singe/thérapie , Syndrome d'immunodéficience acquise du singe/virologie , Virus de l'immunodéficience simienne/génétique , Virus de l'immunodéficience simienne/immunologie , Animaux , Antirétroviraux/usage thérapeutique , Numération des lymphocytes CD4 , Lymphocytes T CD4+/immunologie , Codon stop , Noeuds lymphatiques/virologie , Macaca mulatta , ARN viral/sang , Rectum/virologie , Syndrome d'immunodéficience acquise du singe/sang , Syndrome d'immunodéficience acquise du singe/traitement médicamenteux , Virus de l'immunodéficience simienne/physiologie , Charge virale , Protéines virales régulatrices ou accessoires/génétique , Protéines virales régulatrices ou accessoires/immunologie , Virémie/sang , Virémie/immunologie , Virémie/thérapie , Virémie/virologie , Réplication viraleRÉSUMÉ
Human interleukin 15 (IL-15) circulates in blood as a stable molecular complex with the soluble IL-15 receptor alpha (sIL-15Rα). This heterodimeric IL-15:sIL-15Rα complex (hetIL-15) shows therapeutic potential by promoting the growth, mobilization and activation of lymphocytes and is currently evaluated in clinical trials. Favorable pharmacokinetic properties are associated with the heterodimeric formation and the glycosylation of hetIL-15, which, however, remains largely uncharacterized. We report the site-specific N- and O-glycosylation of two clinically relevant large-scale preparations of HEK293-derived recombinant human hetIL-15. Intact IL-15 and sIL-15Rα and derived glycans and glycopeptides were separately profiled using multiple LC-MS/MS strategies. IL-15 Asn79 and sIL-15Rα Asn107 carried the same repertoire of biosynthetically-related N-glycans covering mostly α1-6-core-fucosylated and ß-GlcNAc-terminating complex-type structures. The two potential IL-15 N-glycosylation sites (Asn71 and Asn112) located at the IL-2 receptor interface were unoccupied. Mass analysis of intact IL-15 confirmed its N-glycosylation and suggested that Asn79-glycosylation partially prevents Asn77-deamidation. IL-15 contained no O-glycans, whereas sIL-15Rα was heavily O-glycosylated with partially sialylated core 1 and 2-type mono- to hexasaccharides on Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160. The sialoglycans displayed α2-3- and α2-6-NeuAc-type sialylation. Non-human, potentially immunogenic glycoepitopes (e.g. N-glycolylneuraminic acid and α-galactosylation) were not displayed by hetIL-15. Highly reproducible glycosylation of IL-15 and sIL-15Rα of two batches of hetIL-15 demonstrated consistent manufacturing and purification. In conclusion, we document the heterogeneous and reproducible N- and O-glycosylation of large-scale preparations of the therapeutic candidate hetIL-15. Site-specific mapping of these molecular features is important to evaluate the consistent large-scale production and clinical efficacy of hetIL-15.
Sujet(s)
Interleukine-15/métabolisme , Maturation post-traductionnelle des protéines , Récepteurs à l'interleukine-15/métabolisme , Acétyl-glucosamine/analogues et dérivés , Acétyl-glucosamine/composition chimique , Acétyl-glucosamine/métabolisme , Glycosylation , Cellules HEK293 , Humains , Interleukine-15/composition chimique , Liaison aux protéines , Récepteurs à l'interleukine-15/composition chimique , Protéines recombinantesRÉSUMÉ
Human immunodeficiency virus (HIV) and Simian immunodeficiency virus (SIV) disease progression is associated with multifocal damage to the gastrointestinal tract epithelial barrier that correlates with microbial translocation and persistent pathological immune activation, but the underlying mechanisms remain unclear. Investigating alterations in mucosal immunity during SIV infection, we found that damage to the colonic epithelial barrier was associated with loss of multiple lineages of interleukin (IL)-17-producing lymphocytes, cells that microarray analysis showed expressed genes important for enterocyte homeostasis, including IL-22. IL-22-producing lymphocytes were also lost after SIV infection. Potentially explaining coordinate loss of these distinct populations, we also observed loss of CD103+ dendritic cells (DCs) after SIV infection, which associated with the loss of IL-17- and IL-22-producing lymphocytes. CD103+ DCs expressed genes associated with promotion of IL-17/IL-22+ cells, and coculture of CD103+ DCs and naïve T cells led to increased IL17A and RORc expression in differentiating T cells. These results reveal complex interactions between mucosal immune cell subsets providing potential mechanistic insights into mechanisms of mucosal immune dysregulation during HIV/SIV infection, and offer hints for development of novel therapeutic strategies to address this aspect of AIDS virus pathogenesis.
Sujet(s)
Côlon/immunologie , Cellules dendritiques/immunologie , Entérocytes/immunologie , Immunité muqueuse , Syndrome d'immunodéficience acquise du singe/immunologie , Virus de l'immunodéficience simienne/physiologie , Cellules Th17/immunologie , Animaux , Antigènes CD/immunologie , Différenciation cellulaire , Lignage cellulaire , Techniques de coculture , Côlon/anatomopathologie , Côlon/virologie , Cellules dendritiques/anatomopathologie , Cellules dendritiques/virologie , Entérocytes/anatomopathologie , Entérocytes/virologie , Régulation de l'expression des gènes , Intégrines alpha/déficit , Intégrines alpha/immunologie , Interleukine-17/déficit , Interleukine-17/génétique , Interleukine-17/immunologie , Interleukines/déficit , Interleukines/génétique , Interleukines/immunologie , Macaca mulatta , Membre-3 du groupe F de la sous-famille-1 de récepteurs nucléaires/génétique , Membre-3 du groupe F de la sous-famille-1 de récepteurs nucléaires/immunologie , Syndrome d'immunodéficience acquise du singe/anatomopathologie , Syndrome d'immunodéficience acquise du singe/virologie , Cellules Th17/anatomopathologie , Cellules Th17/virologie ,RÉSUMÉ
Development of a microbicide that prevents rectal transmission of human immunodeficiency virus (HIV) is a vital component in reducing HIV spread. We recently demonstrated that a formulation of the nonnucleoside reverse transcriptase inhibitor (NNRTI) MIV-150 in carrageenan reduced vaginal infection of macaques with simian immunodeficiency virus SIVmac239 with HIV-1(HxB2) reverse transcriptase (SHIV-RT). Herein, we performed the first testing of MIV-150-carrageenan against rectal infection. Rhesus macaques were treated rectally with MIV-150-carrageenan or methyl cellulose (MC) placebo gel up to 4 h prior to rectal challenge with 10³ or 10(4) 50% tissue culture infective doses (TCID50) of SHIV-RT. Infection was assessed by measuring plasma virus RNA as well as T and B cell responses. MIV-150-carrageenan protected all animals challenged with 10³ TCID(50 when gel was applied either 30 min or 4 h prior to challenge, while 100% of the MC-treated animals became infected (n = 4 each; P < 0.03). Partial protection (2 of 4 animals) by MIV-150-carrageenan was observed for rectal challenge with 10-fold more virus applied 4 h after the gel. Sequencing of the RT gene from plasma virus RNA isolated at peak viremia confirmed that both of these animals (like infected MC controls) were infected with wild-type virus. Infection correlated with the development of SIV-specific T and B cell responses. MIV-150 was detected in the rectal fluids and tissues 4 h after gel application but was not detected in the blood at any time (0.5 to 24 h). These data are promising for the development of NNRTI-containing gels to prevent rectal HIV transmission.
Sujet(s)
Anti-infectieux locaux/administration et posologie , Carragénane/administration et posologie , Gels/administration et posologie , Pyridines/administration et posologie , Syndrome d'immunodéficience acquise du singe/prévention et contrôle , Virus de l'immunodéficience simienne/effets des médicaments et des substances chimiques , Urée/analogues et dérivés , Administration par voie rectale , Animaux , Anti-infectieux locaux/pharmacologie , Lymphocytes B/immunologie , Carragénane/pharmacologie , Gels/pharmacologie , Macaca mulatta , Placebo/administration et posologie , Plasma sanguin/virologie , Pyridines/pharmacologie , ARN viral/sang , Syndrome d'immunodéficience acquise du singe/transmission , Lymphocytes T/immunologie , Urée/administration et posologie , Urée/pharmacologieRÉSUMÉ
The MLV-related retrovirus, XMRV, was recently identified and reported to be associated with both prostate cancer and chronic fatigue syndrome. At the National Cancer Institute-Frederick, MD (NCI-Frederick), we developed highly sensitive methods to detect XMRV nucleic acids, antibodies, and replication competent virus. Analysis of XMRV-spiked samples and/or specimens from two pigtail macaques experimentally inoculated with 22Rv1 cell-derived XMRV confirmed the ability of the assays used to detect XMRV RNA and DNA, and culture isolatable virus when present, along with XMRV reactive antibody responses. Using these assays, we did not detect evidence of XMRV in blood samples (N = 134) or prostate specimens (N = 19) from two independent cohorts of patients with prostate cancer. Previous studies detected XMRV in prostate tissues. In the present study, we primarily investigated the levels of XMRV in blood plasma samples collected from patients with prostate cancer. These results demonstrate that while XMRV-related assays developed at the NCI-Frederick can readily measure XMRV nucleic acids, antibodies, and replication competent virus, no evidence of XMRV was found in the blood of patients with prostate cancer.
RÉSUMÉ
Pigtail macaques (PTMs) rapidly progress to AIDS after simian immunodeficiency virus (SIV) infection. Given the strong association between human immunodeficiency virus (HIV) and SIV disease progression and microbial translocation and immune activation, we assessed whether high basal levels of immune activation and microbial translocation exist in PTMs. We found that before SIV infection, PTMs had high levels of microbial translocation that correlated with significant damage to the structural barrier of the gastrointestinal tract. Moreover, this increased microbial translocation correlated with high levels of immune activation and was associated with high frequencies of interleukin-17-producing T cells. These data highlight the relationship among mucosal damage, microbial translocation and systemic immune activation in the absence of SIV replication, and underscore the importance of microbial translocation in the rapid course of disease progression in SIV-infected PTMs. Furthermore, these data suggest that PTM may be an ideal model to study therapeutic interventions aimed at decreasing microbial translocation-induced immune activation.
Sujet(s)
Muqueuse intestinale/immunologie , Syndrome d'immunodéficience acquise du singe/immunologie , Virus de l'immunodéficience simienne/immunologie , Lymphocytes T/métabolisme , Syndrome d'immunodéficience acquise/immunologie , Animaux , Translocation bactérienne/immunologie , Modèles animaux de maladie humaine , Évolution de la maladie , VIH (Virus de l'Immunodéficience Humaine)/immunologie , Humains , Interleukine-17/biosynthèse , Activation des lymphocytes , Macaca nemestrina , Lymphocytes T/immunologie , Lymphocytes T/anatomopathologie , Lymphocytes T/virologieRÉSUMÉ
BACKGROUND: Human immuno deficiency virus and simian immunodeficiency virus infections are characterized by a severe loss of Th-17 cells (IL-17(+)CD4(+) T cells) that has been associated with disease progression and systemic dissemination of bacterial infections. Anti-retroviral therapy (ART) has led to repopulation of CD4(+) T cells in peripheral tissues with little sustainable repopulation in mucosal tissues. Given the central importance of Th-17 cells in mucosal homeostasis, it is not known if the failure of ART to permanently repopulate mucosal tissues is associated with a failure to restore Th-17 cells that are lost during infection. METHODS: Dynamics of alpha4(+)beta7(hi) CD4(+) T cells in peripheral blood of SIV infected rhesus macaques were evaluated and compared to animals that were treated with ART. The frequency of Th-17 and Tc-17 cells was determined following infection and after therapy. Relative expression of IL-21, IL-23, and TGFbeta was determined using Taqman PCR. RESULTS: Treatment of SIV infected rhesus macaques with anti-retroviral therapy was associated with a substantial repopulation of mucosal homing alpha4(+)beta7(hi)CD4(+) T cells in peripheral blood. This repopulation, however, was not accompanied by a restoration of Th-17 responses. Interestingly, SIV infection was associated with an increase in Tc-17 responses (IL-17(+)CD8(+) T cells) suggesting to a skewing in the ratio of Th-17: Tc-17 cells from a predominantly Th-17 phenotype to a predominantly Tc-17 phenotype. Surprisingly, Tc-17 responses remained high during the course of therapy suggesting that ART failed to correct the imbalance in Th-17 : Tc-17 responses induced following SIV infection. CONCLUSIONS: ART was associated with substantial repopulation of alpha4(+)beta7(hi) CD4(+) T cells in peripheral blood with little or no rebound of Th-17 cells. On the other hand, repopulation of alpha4(+)beta7(hi) CD4(+) T cells was accompanied by persistence of high levels of Tc-17 cells in peripheral blood. The dysregulation of Th-17 and Tc-17 responses likely plays a role in disease progression.
Sujet(s)
Antirétroviraux/usage thérapeutique , Interleukine-17/métabolisme , Syndrome d'immunodéficience acquise du singe/traitement médicamenteux , Lymphocytes T cytotoxiques , Lymphocytes T auxiliaires , Animaux , Rapport CD4-CD8 , Macaca mulatta , Syndrome d'immunodéficience acquise du singe/immunologie , Virus de l'immunodéficience simienne , Charge viraleRÉSUMÉ
Human immunodeficiency virus/simian immunodeficiency virus (HIV/SIV) infections are believed to infect minimally activated CD4(+) T cells after viral entry. Not much is known about why SIV selectively targets these cells. Here we show that CD4(+) T cells that express high levels of the alpha4beta7 heterodimer are preferentially infected very early during the course of SIV infection. At days 2-4 post infection, alpha4(+)beta7(hi)CD4(+) T cells had approximately 5x more SIV-gag DNA than beta7(-)CD4(+) T cells. alpha4(+)beta7(hi)CD4(+) T cells displayed a predominantly central memory (CD45RA(-)CD28(+)CCR7(+)) and a resting (CD25(-)CD69(-)HLA-DR(-)Ki-67(-)) phenotype. Although the expression of detectable CCR5 was variable on alpha4(+)beta7(hi) and beta7(-)CD4(+) T cells, both CCR5(+) and CCR5(-) subsets of alpha4(+)beta7(hi) and beta7(-)CD4(+) T cells were found to express sufficient levels of CCR5 mRNA, suggesting that both these subsets could be efficiently infected by SIV. In line with this, we found similar levels of SIV infection in beta7(-)CD4(+)CCR5(+) and beta7(-)CD4(+)CCR5(-) T cells. alpha4beta7(hi)CD4(+) T cells were found to harbor most T helper (Th)-17 cells that were significantly depleted during acute SIV infection. Taken together, our results show that resting memory alpha4(+)beta7(hi)CD4(+) T cells in the blood are preferentially infected and depleted during acute SIV infection, and the loss of these cells alters the balance between Th-17 and Th-1 responses, thereby contributing to disease pathogenesis.
Sujet(s)
Mémoire immunologique , Récepteur lymphocytaire T antigène, alpha-bêta/immunologie , Récepteurs d'écotaxie des lymphocytes/immunologie , Syndrome d'immunodéficience acquise du singe/immunologie , Virus de l'immunodéficience simienne/physiologie , Sous-populations de lymphocytes T/virologie , Lymphocytes T auxiliaires/virologie , Attachement viral , Maladie aigüe , Animaux , Numération des lymphocytes CD4 , Interactions hôte-pathogène/immunologie , Immunophénotypage , Interféron gamma/métabolisme , Interleukine-17/métabolisme , Macaca mulatta , ARN messager/biosynthèse , Récepteurs CCR5/analyse , Récepteurs CCR5/génétique , Récepteurs d'écotaxie des lymphocytes/analyse , Syndrome d'immunodéficience acquise du singe/virologie , Virus de l'immunodéficience simienne/immunologie , Sous-populations de lymphocytes T/immunologie , Sous-populations de lymphocytes T/métabolisme , Lymphocytes T auxiliaires/immunologie , Lymphocytes T auxiliaires/métabolismeRÉSUMÉ
Dendritic cells (DCs) play a key role in innate immune responses, and their interactions with T cells are critical for the induction of adaptive immunity. However, immunodeficiency viruses are efficiently captured by DCs and can be transmitted to and amplified in CD4(+) T cells, with potentially deleterious effects on the induction of immune responses. In DC-T-cell cocultures, contact with CD4(+), not CD8(+), T cells preferentially facilitated virus movement to and release at immature and mature DC-T-cell contact sites. This occurred within 5 min of DC-T-cell contact. While the fusion inhibitor T-1249 did not prevent virus capture by DCs or the release of viruses at the DC-T-cell contact points, it readily blocked virus transfer to and amplification in CD4(+) T cells. Higher doses of T-1249 were needed to block the more robust replication driven by mature DCs. Virus accumulated in DCs within T-1249-treated cocultures but these DCs were actually less infectious than DCs isolated from untreated cocultures. Importantly, T-1249 did not interfere with the stimulation of virus-specific CD4(+) and CD8(+) T-cell responses when present during virus-loading of DCs or for the time of the DC-T-cell coculture. These results provide clues to identifying strategies to prevent DC-driven virus amplification in CD4(+) T cells while maintaining virus-specific immunity, an objective critical in the development of microbicides and therapeutic vaccines.
Sujet(s)
Antiviraux/pharmacologie , Cellules dendritiques/effets des médicaments et des substances chimiques , Cellules dendritiques/immunologie , VIH (Virus de l'Immunodéficience Humaine)/physiologie , Virus de l'immunodéficience simienne/physiologie , Lymphocytes T/effets des médicaments et des substances chimiques , Lymphocytes T/immunologie , Animaux , Cellules cultivées , Techniques de coculture , Cellules dendritiques/ultrastructure , Cellules dendritiques/virologie , Femelle , Protéine d'enveloppe gp41 du VIH/pharmacologie , Humains , Macaca mulatta , Mâle , Microscopie électronique à transmission , Fragments peptidiques/pharmacologie , Lymphocytes T/ultrastructure , Facteurs tempsRÉSUMÉ
The development of HIV vaccines is an urgent priority and there is need to generate reagents representing multiple subtypes that can be used to screen HIV-1-specific responses. We used Aldrithiol-2 (AT-2), a mild oxidizing reagent, to eliminate the infectivity of HIV while maintaining its structure and ability to be processed for presentation to T cells. Inactivated subtype A, B, and D viruses were evaluated for their ability to stimulate T cell responses in PBMC samples from 18 U.S. subjects infected with HIV-1 subtype B and 32 Ugandan subjects infected with subtypes A and D or recombinants AC and AD. Five HIV-1-negative samples were also analyzed. T cell responses to AT-2-inactivated viral isolates were monitored by interferon-gamma (IFN-gamma) intracellular cytokine secretion (ICS) analysis; matched microvesicle preparations served as negative controls. Among the 18 subtype B infected subjects, 39% had CD3(+) CD4 (+) IFN-gamma responses and 67% had CD3(+) CD8(+) IFN-gamma responses. Of the 32 Ugandan subjects, 34% demonstrated CD3(+) CD4(+) IFN-gamma responses and 78% demonstrated CD3(+) CD8(+) IFN-gamma responses. Both subtype-specific and cross-reactive responses were observed. Responses to the AT-2 viruses tended to be lower in magnitude than those detected by a set of overlapping gag peptides. Robust lymphoproliferative responses to AT-2 viruses were seen in a subset of subjects. In conclusion, AT-2-inactivated HIV-1 virions stimulated both CD4 and CD8 HIV-1-specific responses and may provide an additional reagent for screening HIV-1-specific responses in HIV seropositives and vaccinees.
Sujet(s)
Lymphocytes T CD4+/immunologie , Lymphocytes T CD8+/immunologie , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/immunologie , Inactivation virale , 2,2'-Bipyridine/analogues et dérivés , 2,2'-Bipyridine/pharmacologie , Vaccins contre le SIDA , Lymphocytes T CD4+/virologie , Lymphocytes T CD8+/virologie , Cellules cultivées , Disulfures/pharmacologie , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/classification , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/effets des médicaments et des substances chimiques , Humains , Interféron gamma/métabolisme , Oxydants/pharmacologieRÉSUMÉ
Cytosine-phosphate-guanine class C (CpG-C) immunostimulatory sequence oligodeoxynucleotides (ISS-ODNs) activate human B cells and dendritic cells (DCs), properties that suggest potential use as a novel adjuvant to enhance vaccine efficacy. After demonstrating that the CpG-C ISS-ODN C274 activates macaque DCs, we examined in vitro activation of macaque B cells by C274 as a prelude to evaluation of this molecule as an adjuvant in the testing of candidate human immunodeficiency virus vaccines in the rhesus macaque-simian immunodeficiency virus (SIV) model. C274 induced macaque CD20(+) B cells to proliferate more strongly than CD40 ligand or CpG-B ISS-ODN. C274 enhanced B cell survival; increased viability was most evident after 3-7 days of culture. Increased expression of CD40, CD80, and CD86 by B cells was apparent within 24 h of exposure to C274 and persisted for up to 1 week. C274-stimulated, B cell-enriched and peripheral blood mononuclear cell suspensions from naïve and immunodeficiency virus-infected monkeys secreted several cytokines [e.g., interleukin (IL)-3, IL-6, IL-12, interferon-alpha] and chemokines [e.g., monocyte chemoattractant protein-1/CC chemokine ligand 2 (CCL2), macrophage-inflammatory protein-1alpha/CCL3, IL-8/CXC chemokine ligand 8]. In comparison, exposure of macaque B cells to SIV had minimal impact on surface phenotype, despite inducing cytokine and chemokine production in cells from infected and uninfected animals. These observations emphasize the need to identify strategies to optimally boost immune function, as immunodeficiency viruses themselves only partially activate B cells and DCs. The ability of C274 to stimulate B cells and DCs in healthy and infected monkeys suggests its possible use as a broad-acting adjuvant to be applied in the rhesus macaque model for the development of preventative and therapeutic vaccines.
Sujet(s)
Vaccins contre le SIDA/pharmacologie , Lymphocytes B/effets des médicaments et des substances chimiques , Infections à VIH/immunologie , Oligodésoxyribonucléotides/pharmacologie , Oligonucléotides/pharmacologie , Virus de l'immunodéficience simienne/immunologie , Animaux , Lymphocytes B/immunologie , Ligand de CD40/pharmacologie , Prolifération cellulaire/effets des médicaments et des substances chimiques , Cellules cultivées , Chimiokines/immunologie , Maladie chronique , Cytokines/immunologie , Cellules dendritiques/effets des médicaments et des substances chimiques , Cellules dendritiques/immunologie , Modèles animaux de maladie humaine , Femelle , Techniques in vitro , Macaca mulatta , Mâle , Virus de l'immunodéficience simienne/effets des médicaments et des substances chimiquesRÉSUMÉ
Dendritic cells (DCs) infected with recombinant avipox vectors express the introduced genes and activate antigen-specific T cells. DCs exhibit distinct differentiation-dependent immune functions. Moreover, immature DCs are readily infected by canarypox vectors, but undergo tumor necrosis factor (TNF)-alpha-dependent death, while fewer mature DCs get infected and resist dying. A pilot study was performed using the rhesus macaque system to explore whether immature and mature DCs infected with SIV-recombinant canarypox (vCP180) ex vivo could induce primary virus-specific immune responses in vivo. After subcutaneous (sc) reinjection, functional monocyte-derived DCs migrated to lymph nodes (LNs) within 1-2 days and primed T cells in vivo. This was observed by monitoring dye-labeled DCs in the draining LNs and tetanus toxoid (TT)-specific T cell responses after injection of TT-loaded DCs. DCs from simian immunodeficiency virus (SIV)-naïve rhesus macaques were infected with vCP180 (SIVmac142 gag, pol, and env genes), and sc reinjected into donor animals. Low-level SIV-specific T cell proliferation, but little if any interferon (IFN)-gamma production was detected. DCs pulsed with vCP180 in combination with TT and keyhole limpet hemocyanin (KLH) (to activate additional T cells and provide "helper" cytokines) induced SIV-, TT-, and KLH-specific T cell responses, including IFN-gamma responses not seen when vCP180-carrying DCs were used alone. Interleukin (IL)-10 and low-level antibody responses were also observed. This pilot study provides the proof of principle that sc injected ex vivo SIV-recombinant canarypox-infected DCs safely induce low-level SIV-specific immune responses in vivo.
Sujet(s)
Virus de la variole du canari/immunologie , Cellules dendritiques/virologie , Virus de l'immunodéficience simienne/immunologie , Animaux , Virus de la variole du canari/génétique , Virus de la variole du canari/physiologie , Cellules dendritiques/immunologie , Vecteurs génétiques , Macaca mulatta , Virus de l'immunodéficience simienne/génétique , Virus de l'immunodéficience simienne/physiologie , Lymphocytes T cytotoxiques/immunologie , Lymphocytes T cytotoxiques/physiologie , Vaccins synthétiquesRÉSUMÉ
Like human immunodeficiency virus infection of humans, infection of rhesus macaques with pathogenic simian immunodeficiency virus (SIV) strains typically results in persistent progressive infection, leading to clinically significant immunosuppression. In previous studies, we administered short term anti-retroviral treatment, shortly after intravenous inoculation with SIVsmE660, in an effort to allow immunologic sensitization under conditions not characterized by overwhelming cytopathic infection compromising the developing immune response. We showed that such treatment allowed control of off treatment viremia and was associated with resistance to rechallenge. Control of off treatment viremia was associated, at least in part, with CD8+ lymphocytes, based on in vivo CD8 depletion studies. In the present study, six rhesus macaques were infected intravenously with 100 MID50 of SIVmac239; four then received 30 days of treatment with tenofovir 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA); 20-30 mg/kg, subcutaneously) starting 24 hours post-inoculation. Tenofovir-treated animals showed low (<500 copy Eq/ml) or undetectable (<100 copy Eq/ml) plasma SIV RNA levels during treatment, with undetectable plasma viremia following discontinuation of treatment. Plasma SIV RNA remained <100 copy Eq/ml, even after depletion of CD8+ lymphocytes, 6 weeks after discontinuation of tenofovir treatment. In contrast to untreated infected control animals that showed substantial depletion of CD4+ T cells from gut-associated lymphoid tissues (GALT), tenofovir-treated animals showed sparing of GALT CD4+ T cells both during the treatment period and in the off treatment follow-up period. However, in contrast to earlier results with animals infected with SIVsmE660, in the present study, the animals did not develop readily measurable cellular anti-SIV immune responses, and did not resist homologous rechallenge with SIVmac239, administered 44 weeks after the initial infection. Differences in the animals and virus strains employed may in part account for the differences in results observed. Comparative analysis of virologic and immunologic parameters in this model system may provide important insights for understanding the basis of effective immunologic control of SIV infection.
Sujet(s)
Adénine/analogues et dérivés , Adénine/usage thérapeutique , Agents antiVIH/usage thérapeutique , Lymphocytes T CD4+/effets des médicaments et des substances chimiques , Produits du gène env/immunologie , Macaca mulatta/immunologie , Macaca mulatta/virologie , Phosphonates , Composés organiques du phosphore/usage thérapeutique , Protéines oncogènes des retroviridae/immunologie , Syndrome d'immunodéficience acquise du singe/traitement médicamenteux , Protéines de fusion virale/immunologie , Animaux , Amorces ADN , Produits du gène gag/immunologie , Intestins/virologie , Tissu lymphoïde/effets des médicaments et des substances chimiques , Mâle , Syndrome d'immunodéficience acquise du singe/immunologie , Virus de l'immunodéficience simienne/effets des médicaments et des substances chimiques , Ténofovir , Charge virale , Virémie/virologieRÉSUMÉ
Two subspecies of rhesus (Rh) macaques, the Chinese (Ch) and Indian (Ind) subspecies were infected intravenously with 100TCID50 SIVmac239. CD4+, CD8+ T cells, plasma viral loads, depletion of intestinal lymphocytes with memory phenotype, humoral immune responses and clinical courses were monitored for 600 days. The pathogenesis of SIVmac was also compared with primary human immunodeficiency virus (HIV) infection of humans. Plasma viral loads in Ch Rh were lower in the acute and chronic phases compared with Ind Rh. SIVmac pathogenesis in Ch Rh was closer to virus loads in untreated HIV infected humans. Ch Rh had higher CD4/CD8 ratios, stronger antibody responses and interestingly, less depletion of intestinal memory CCR5+ CD4+ T lymphocytes compared with Ind Rh. One Ch Rh developed B cell origin lymphoma at 570 days post-infection, the first such report in this subspecies. Three of four Ind Rh developed AIDS within 6 months. The findings indicate that Ch Rh are more resistant to SIVmac pathogenesis compared with Ind Rh and that Ch Rh paralleled HIV-1 infections in untreated adult humans. The SIVmac infected Ch Rh subspecies are an acceptable model for HIV/AIDS.
Sujet(s)
Lymphome B/complications , Macaca mulatta/virologie , Syndrome d'immunodéficience acquise du singe/complications , Syndrome d'immunodéficience acquise du singe/physiopathologie , Virus de l'immunodéficience simienne/pathogénicité , Vieillissement , Animaux , Anticorps antiviraux/analyse , Anticorps antiviraux/immunologie , Rapport CD4-CD8 , Chine , Test ELISA , Femelle , Cytométrie en flux , Immunohistochimie , Études longitudinales , Lymphome B/immunologie , Lymphome B/anatomopathologie , Lymphome B/virologie , Macaca mulatta/classification , Mâle , ARN viral , Syndrome d'immunodéficience acquise du singe/immunologie , Syndrome d'immunodéficience acquise du singe/virologie , Virus de l'immunodéficience simienne/classification , Virus de l'immunodéficience simienne/immunologie , Spécificité d'espèce , Facteurs temps , Charge viraleRÉSUMÉ
A novel type of whole inactivated simian immunodeficiency virus (SIV) virion vaccine immunogen with functional envelope glycoproteins was evaluated, without adjuvant, in rhesus macaques. Immunogens included purified inactivated virions of SIVmac239, a designed mutant of SIVmac239 with gp120 carbohydrate attachment sites deleted (SIVmac239 g4,5), and SIVmneE11S. The vaccines were noninfectious, safe, and immunogenic, inducing antibody responses and cellular responses, including responses by CD8+ lymphocytes. Interpretation of protective efficacy following intrarectal challenge was complicated by incomplete take of the challenge in some SIV naïve controls.
Sujet(s)
Produits du gène env/immunologie , Macaca mulatta/immunologie , Macaca mulatta/virologie , Vaccins contre le SIDA simien/effets indésirables , Vaccins contre le SIDA simien/immunologie , Virus de l'immunodéficience simienne/immunologie , Vaccins atténués/effets indésirables , Vaccins atténués/immunologie , Administration par voie rectale , Animaux , Anticorps antiviraux/immunologie , Lymphocytes T CD8+/immunologie , Chromatographie en phase liquide à haute performance , Test ELISA , Femelle , Activation des lymphocytes , Mâle , ARN viral/sang , Syndrome d'immunodéficience acquise du singe/immunologie , Syndrome d'immunodéficience acquise du singe/prévention et contrôle , Syndrome d'immunodéficience acquise du singe/virologie , Virus de l'immunodéficience simienne/physiologie , Facteurs temps , Charge viraleRÉSUMÉ
As potential targets for human immunodeficiency virus type 1 and simian immunodeficiency virus (HIV-1 and SIV), dendritic cells (DCs) likely play a significant role in the onset and spread of infection as well as in the induction of antiviral immunity. Using the SIV-macaque system to study the very early events in DC-virus interactions, we compared chemically inactivated SIV having conformationally and functionally intact envelope glycoproteins (2,2'-dithiodipyridine [AT-2] SIV) to infectious and heat-treated SIV. Both human and macaque DCs interact similarly with SIV without detectable effects on DC viability, phenotype, or endocytic function. As assessed by measuring cell-associated viral RNA, considerable amounts of virus are captured by the DCs and this is reduced when the virus is heat treated or derived from a strain that expresses low levels of envelope glycoprotein. Immunostaining for SIV proteins and electron microscopy indicated that few intact virus particles are retained at the periphery of the endocytically active, immature DCs. This contrasts with a perinuclear localization of numerous virions in large vesicular compartments deeper within mature DCs (in which macropinocytosis is down-regulated). Both immature and mature DCs are capable of clathrin-coated pit-mediated uptake of SIV, supporting the notion that the receptor-mediated uptake of virus can occur readily in mature DCs. While large numbers of whole viruses were preferentially found in mature DCs, both immature and mature DCs contained similar amounts of viral RNA, suggesting that different uptake/virus entry mechanisms are active in immature and mature DCs. These findings have significant implications for cell-to-cell transmission of HIV-1 and SIV and support the use of AT-2 SIV, an authentic but noninfectious form of virus, as a useful tool for studies of processing and presentation of AT-2 SIV antigens by DCs.
Sujet(s)
2,2'-Bipyridine/analogues et dérivés , 2,2'-Bipyridine/pharmacologie , Différenciation cellulaire , Cellules dendritiques/cytologie , Cellules dendritiques/virologie , Disulfures/pharmacologie , Virus de l'immunodéficience simienne/effets des médicaments et des substances chimiques , Virus de l'immunodéficience simienne/pathogénicité , Animaux , Lignée cellulaire , Cellules dendritiques/ultrastructure , Endocytose , Femelle , Humains , Macaca mulatta , Mâle , Fusion membranaire , Microscopie électronique , Microscopie de fluorescence , Syndrome d'immunodéficience acquise du singe/virologie , Virus de l'immunodéficience simienne/immunologie , Virus de l'immunodéficience simienne/physiologie , Protéines de l'enveloppe virale/métabolismeRÉSUMÉ
Transient antiretroviral treatment with tenofovir, (R)-9-(2-phosphonylmethoxypropyl)adenine, begun shortly after inoculation of rhesus macaques with the highly pathogenic simian immunodeficiency virus (SIV) isolate SIVsmE660, facilitated the development of SIV-specific lymphoproliferative responses and sustained effective control of the infection following drug discontinuation. Animals that controlled plasma viremia following transient postinoculation treatment showed substantial resistance to subsequent intravenous rechallenge with homologous (SIVsmE660) and highly heterologous (SIVmac239) SIV isolates, up to more than 1 year later, despite the absence of measurable neutralizing antibody. In some instances, resistance to rechallenge was observed despite the absence of detectable SIV-specific binding antibody and in the face of SIV lymphoproliferative responses that were low or undetectable at the time of challenge. In vivo monoclonal antibody depletion experiments demonstrated a critical role for CD8(+) lymphocytes in the control of viral replication; plasma viremia rose by as much as five log units after depletion of CD8(+) cells and returned to predepletion levels (as low as <100 copy Eq/ml) as circulating CD8(+) cells were restored. The extent of host control of replication of highly pathogenic SIV strains and the level of resistance to heterologous rechallenge achieved following transient postinoculation treatment compared favorably to the results seen after SIVsmE660 and SIVmac239 challenge with many vaccine strategies. This impressive control of viral replication was observed despite comparatively modest measured immune responses, less than those often achieved with vaccination regimens. The results help establish the underlying feasibility of efforts to develop vaccines for the prevention of AIDS, although the exact nature of the protective host responses involved remains to be elucidated.
Sujet(s)
Adénine/usage thérapeutique , Agents antiVIH/usage thérapeutique , Lymphocytes T CD8+/physiologie , Phosphonates , Composés organiques du phosphore/usage thérapeutique , Syndrome d'immunodéficience acquise du singe/immunologie , Adénine/analogues et dérivés , Animaux , Femelle , Macaca mulatta , Syndrome d'immunodéficience acquise du singe/traitement médicamenteux , Ténofovir , Réplication viraleRÉSUMÉ
In this report, three Mamu-A*01(+) rhesus macaques were examined to compare the emergence of simian immunodeficiency virus (SIV)-specific CD8(+) T cells in the intestines and blood in early SIV infection using a major histocompatibility complex class I tetramer complexed with the Gag(181-189) peptide. Fourteen days after intravenous inoculation with SIVmac251, large numbers of SIV Gag(181-189)-specific CD8(+) T cells were detected in the intestinal mucosa (3.1 to 11.5% of CD3(+) CD8(+) lymphocytes) as well as in the blood (3.1 to 13.4%) of all three macaques. By 21 days postinoculation, levels of tetramer-binding cells had dropped in both the intestines and blood. At day 63, however, levels of SIV Gag(181-189)-specific CD8(+) T cells in the intestines had rebounded in all three macaques to levels that were higher (8.6 to 18.7%) than those at day 21. In contrast, percentages of tetramer-binding cells in the peripheral blood remained comparatively stable (2.5 to 4.5%) at this time point. In summary, SIV Gag(181-189)-specific CD8(+) T cells appeared in both the intestinal mucosa and peripheral blood at a comparable rate and magnitude in primary SIV infection. Given that the intestine is a major site of early viral replication as well as the site where most of the total body lymphocyte pool resides, these data indicate that it is also an early and important site of development of antiviral immune responses.
Sujet(s)
Lymphocytes T CD8+/immunologie , Intestins/immunologie , Syndrome d'immunodéficience acquise du singe/immunologie , Virus de l'immunodéficience simienne/immunologie , Animaux , Produits du gène gag/immunologie , Intestins/virologie , Cinétique , Macaca , Mâle , Fragments peptidiques/immunologieRÉSUMÉ
Here we provide the first report of protection against a vaginal challenge with a highly virulent simian immunodeficiency virus (SIV) by using a vaccine vector. New poliovirus vectors based on Sabin 1 and 2 vaccine strain viruses were constructed, and these vectors were used to generate a series of new viruses containing SIV gag, pol, env, nef, and tat in overlapping fragments. Two cocktails of 20 transgenic polioviruses (SabRV1-SIV and SabRV2-SIV) were inoculated into seven cynomolgus macaques. All monkeys produced substantial anti-SIV serum and mucosal antibody responses. SIV-specific cytotoxic T-lymphocyte responses were detected in three of seven monkeys after vaccination. All 7 vaccinated macaques, as well as 12 control macaques, were challenged vaginally with pathogenic SIVmac251. Strikingly, four of the seven vaccinated animals exhibited substantial protection against the vaginal SIV challenge. All 12 control monkeys became SIV positive. In two of the seven SabRV-SIV-vaccinated monkeys we found no virological evidence of infection following challenge, indicating that these two monkeys were completely protected. Two additional SabRV-SIV-vaccinated monkeys exhibited a pronounced reduction in postacute viremia to <10(3) copies/ml, suggesting that the vaccine elicited an effective cellular immune response. Three of six control animals developed clinical AIDS by 48 weeks postchallenge. In contrast, all seven vaccinated monkeys remained healthy as judged by all clinical parameters. These results demonstrate the efficacy of SabRV as a potential human vaccine vector, and they show that the use of a vaccine vector cocktail expressing an array of defined antigenic sequences can be an effective vaccination strategy in an outbred population.
Sujet(s)
Arénavirus du Nouveau Monde , Vecteurs génétiques , Syndrome d'immunodéficience acquise du singe/prévention et contrôle , Virus de l'immunodéficience simienne , Vaccins antiviraux , Animaux , Arénavirus du Nouveau Monde/génétique , Arénavirus du Nouveau Monde/immunologie , Femelle , Humains , Macaca , Recombinaison génétique , Syndrome d'immunodéficience acquise du singe/immunologie , Syndrome d'immunodéficience acquise du singe/transmission , Virus de l'immunodéficience simienne/immunologie , Vagin/virologieRÉSUMÉ
Human immunodeficiency virus (HIV) infection results in a functional impairment of CD4(+) T cells long before a quantitative decline in circulating CD4(+) T cells is evident. The mechanism(s) responsible for this functional unresponsiveness and eventual depletion of CD4(+) T cells remains unclear. Both direct effects of cytopathic infection of CD4(+) cells and indirect effects in which uninfected "bystander" cells are functionally compromised or killed have been implicated as contributing to the immunopathogenesis of HIV infection. Because T-cell receptor engagement of major histocompatibility complex (MHC) molecules in the absence of costimulation mediated via CD28 binding to CD80 (B7-1) or CD86 (B7-2) can lead to anergy or apoptosis, we determined whether HIV type 1 (HIV-1) virions incorporated MHC class I (MHC-I), MHC-II, CD80, or CD86. Microvesicles produced from matched uninfected cells were also evaluated. HIV infection increased MHC-II expression on T- and B-cell lines, macrophages, and peripheral blood mononclear cells (PBMC) but did not significantly alter the expression of CD80 or CD86. HIV virions derived from all MHC-II-positive cell types incorporated high levels of MHC-II, and both virions and microvesicles preferentially incorporated CD86 compared to CD80. CD45, expressed at high levels on cells, was identified as a protein present at high levels on microvesicles but was not detected on HIV-1 virions. Virion-associated, host cell-derived molecules impacted the ability of noninfectious HIV virions to trigger death in freshly isolated PBMC. These results demonstrate the preferential incorporation or exclusion of host cell proteins by budding HIV-1 virions and suggest that host cell proteins present on HIV-1 virions may contribute to the overall pathogenesis of HIV-1 infection.